TY 2022 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(1) Ed Dandridge Chair of the Board	1.0 ................. 0	X	X
(2) Jerri Johnson BOD MEMBER (VICE CHAIR)	1.0 ................. 0	X	X
(3) Andi Owen BOD Member (ending March 2023)	1.0 ................. 0	X
(4) BJ Schaknowski BOD Member	1.0 ................. 0	X
(5) Boris Dolgonos BOD Member (beginning March 2023)	1.0 ................. 0	X
(6) Christina Minnis BOD Member	1.0 ................. 0	X
(7) Gail Heimann BOD Member	1.0 ................. 0	X
(8) John O'Neill BOD Member (ended April 2022)	1.0 ................. 0	X
(9) Julia Harris BOD Member	1.0 ................. 0	X
(10) Julie Gruber BOD Member	1.0 ................. 0	X
(11) Kristen Racich BOD Member	1.0 ................. 0	X
(12) LaQuenta Jacobs BOD Member (beginning March 2023)	1.0 ................. 0	X
(13) Luke Sauter BOD Member	1.0 ................. 0	X
(14) Lydia The BOD Member	1.0 ................. 0	X
(15) Michelle Bottomley BOD Member	1.0 ................. 0	X
(16) Peter Brundage BOD Member	1.0 ................. 0	X
(17) Renee Baker BOAD Member	1.0 ................. 0	X

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(18) Robyn Shepherd BOD Member	1.0 .......................0	X					0	0
(19) Sean Slovenski BOD Member	1.0 .......................0	X					0	0
(20) Traci Blunt BOD Member	1.0 .......................0	X					0	0
(21) Valerie Rainey BOD Member (beginning March 2023)	1.0 .......................0	X					0	0
(22) Eunice Nakamura General Counsel and Corporate Secretary	55.0 .......................0		X				273,878	23,687
(23) Paula Schneider President and CEO	55.0 .......................0		X				888,164	27,615
(24) Ria Williams Chief Fin & Ops Officer	55.0 .......................0		X				319,076	30,635
(25) Catherine Olivieri SVP, Human Resources	55.0 .......................0			X			277,075	26,419
(26) Lori Maris SVP, OPS SERVICES & SUPPORT	55.0 .......................0			X			240,233	15,349
(27) Victoria Smart SVP, Mission	55.0 .......................0			X			331,477	15,705
(28) Catherine Stone VP, Community Health	55.0 .......................0				X		213,060	13,131
(29) Kari Bodell VP, Development Programs Strategy	55.0 .......................0				X		239,625	14,169
(30) Michelle Strong VP, Marketing Strategy	55.0 .......................0				X		233,180	22,360
(31) Sarah Rosales VP, Corporate Partnerships	55.0 .......................0				X		257,358	29,351
(32) Srinivasu Avadhanula VP, BI Platform & Engineering	55.0 .......................0				X		249,792	23,614
(33) Dana Brown Chief Operating Officer (Term 3/31/22)	0.0 .......................0					X	184,757	5,580

(A) Name and business address	(B) Description of services	(C) Compensation
Event 360 205 N Michigan Ave Chicago,IL60601	Event Management	3,132,937
RKD Group LLC 3400 Waterview Parkway Richardson,TX75080	Consulting	1,014,986
Prometheus Research LLC One Audubon Street 4th Fllor New Haven,CT06511	Technology Services	460,000
MSB Financial Solutions LLC 79 Cherrywood Dr Nashua,NH03062	Software Services	445,942
Ernst & Young 3712 Solutions Center Chicago,IL60677	Acctg & Tax Services	342,243
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 17

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2022

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	63,291,987	59,972,314	50,983,746	99,456,148	111,805,407	385,509,602
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....						0
3	The value of services or facilities furnished by a governmental unit to the organization without charge..						0
4	Total. Add lines 1 through 3	63,291,987	59,972,314	50,983,746	99,456,148	111,805,407	385,509,602
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..						19,028,970
6	Public support. Subtract line 5 from line 4.						366,480,632

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
7	Amounts from line 4..	63,291,987	59,972,314	50,983,746	99,456,148	111,805,407	385,509,602
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	5,221,701	4,928,838	1,217,543	1,156,360	1,438,781	13,963,223
9	Net income from unrelated business activities, whether or not the business is regularly carried on..						0
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..	34,200	86,442	15,070	3,574	26,758	166,044
11	Total support. Add lines 7 through 10						399,638,869

Gross receipts from related activities, etc. (see instructions) ..................

65,072,779

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 6, column (f) divided by line 11, column (f)) .........

91.70 %

Public support percentage for 2020 Schedule A, Part II, line 14 ...............

81.99 %

16a

33 1/3% support test—2022. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2021. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2022. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

10%-facts-and-circumstances test—2021. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990) 2022

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2021 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2022 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2021 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests-2022. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2021. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990) 2022

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2022

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990) 2022

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2022

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2022 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2022	(iii) Distributable Amount for 2022
1 Distributable amount for 2022 from Section C, line 6
2 Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2022:
a From 2017.......
b From 2018.......
c From 2019.......
d From 2020.......
e From 2021.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2022 distributable amount
i Carryover from 2017 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2022 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2022 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2023. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2018.....
b Excess from 2019.....
c Excess from 2020.....
d Excess from 2021.....
e Excess from 2022.....

Schedule A (Form 990) (2022)

Schedule A (Form 990) 2022

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation
Schedule A, Part II, Line 10 Other Income	DESCRIPTION - OTHER INCOME, COLUMN A - 34200.0, COLUMN B - 86442.0, COLUMN C - 15070.0, COLUMN D - 3574.0, COLUMN E - 26758.0, COLUMN F - 166044.0;

Schedule A (Form 990) 2022

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

Schedule B
(Form 990)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... Arrow Bullet

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990) (2022)

Schedule B (Form 990) (2022) Page 2

Name of organization The Susan G Komen Breast Cancer Foundation Inc

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 3

Name of organization The Susan G Komen Breast Cancer Foundation Inc		Employer identification number 75-1835298

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 4


Name of organization The Susan G Komen Breast Cancer Foundation Inc			Employer identification number 75-1835298
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990) (2022)

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV. See instructions for definition of “political campaign activities."

Political campaign activity expenditures. See instructions .................................................................... SchCMd Bullet

Volunteer hours for political campaign activities. See instructions ..................................................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ................................ SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ....................... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .........................................

Yes No

Was a correction made? ......................................................................................................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ............................................................................................................................ SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b........... SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ...................................................................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1
2
3
4
5
6

For Paperwork Reduction Act Notice, see the instructions for Form 990.

Cat. No. 50084S

Schedule C (Form 990) 2021

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......................	15,803	15,803
b	Total lobbying expenditures to influence a legislative body (direct lobbying) ........................	277,717	277,717
c	Total lobbying expenditures (add lines 1a and 1b) ............................................................	293,520	293,520
d	Other exempt purpose expenditures ...............................................................................	103,643,020	103,669,862
e	Total exempt purpose expenditures (add lines 1c and 1d) ..................................................	103,936,540	103,963,382
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000	1,000,000
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................................................	250,000	250,000
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................................................	0	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................................................	0	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ...................................................................................................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total

2a	Lobbying nontaxable amount	1,000,000	1,000,000	1,000,000	1,000,000	4,000,000

b	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000

c	Total lobbying expenditures	343,462	172,474	204,997	293,520	1,014,453

d	Grassroots nontaxable amount	250,000	250,000	250,000	250,000	1,000,000

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000

f	Grassroots lobbying expenditures	86,368	386,160	26,906	15,803	515,237

Schedule C (Form 990) 2021

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes|No

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? ...........................................................................................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ........

Media advertisements? ...................................................................................................

Mailings to members, legislators, or the public? .............................................................................

Publications, or published or broadcast statements? ...........................................................

Grants to other organizations for lobbying purposes? ..........................................................

Direct contact with legislators, their staffs, government officials, or a legislative body? .......................

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ..................

Other activities? ...................................................................................................................

Total. Add lines 1c through 1i ....................................................................................................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 ...........................................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 ...................

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? ........................

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ...............................................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ............................................

Did the organization agree to carry over lobbying and political expenditures from the prior year? .................................

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members ......................................................................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).

Current year .............................................................................................................................

Carryover from last year ............................................................................................................

Total ...........................................................................................................................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ......................................................................................................................

Taxable amount of lobbying and political expenditures. See Instructions .........................................

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation
Schedule C, Part II-A Lobbying Expenses	PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE AND FUND CRITICAL BREAST CANCER RESEARCH.

Schedule C (Form 990) 2021

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2021

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....	1,346,868	1,342,173	1,337,562	1,333,603	1,362,090
b	Contributions ...	2,279,000	0	0	0	0
c	Net investment earnings, gains, and losses	-7,607	10,613	10,279	9,803	-4,016
d	Grants or scholarships ...		0	0	0	0
e	Other expenditures for facilities and programs ...	5,713	5,918	5,668	5,844	24,267
f	Administrative expenses ....		0	0	0	204
g	End of year balance ......	3,612,548	1,346,868	1,342,173	1,337,562	1,333,603

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

27.7 %

Permanent endowment SchDMd Bullet

72.1 %

Term endowment SchDMd Bullet

0.2 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....
b	Buildings ....
c	Leasehold improvements
d	Equipment ....	2,357,161	1,967,638	389,523
e	Other .....	11,575,780	7,611,768	3,964,012
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				4,353,535

Schedule D (Form 990) 2021

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3) Other (A) PRIVATE EQUITY FUND	43,470,000	F
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)	43,470,000

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes

(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	0
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2021

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	127,818,234
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a	-11,884,802
b	Donated services and use of facilities .........	2b	32,764,307
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d	-342,617
e	Add lines 2a through 2d .....................			2e	20,536,888
3	Subtract line 2e from line 1..................			3	107,281,346
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	316,359
b	Other (Describe in Part XIII.) ...........	4b	0
c	Add lines 4a and 4b....................			4c	316,359
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	107,597,705

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	148,480,516
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a	32,485,644
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d	-1,068,997
e	Add lines 2a through 2d....................			2e	31,416,647
3	Subtract line 2e from line 1...................			3	117,063,869
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b	0
c	Add lines 4a and 4b.....................			4c	0
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	117,063,869

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
Schedule D, Part V, Line 4 Intended uses of endowment funds	KOMEN HAS FIVE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, TWO GENERAL ENDOWMENTS, AND A PERPETUAL TRUST. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, THE GENERAL ENDOWMENT AND PERPETUAL TRUST'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES.
Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote	THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2023
Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990	In Kind Services Direct Costs - -342617
Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990	Rescinded Grants - -1101560 Program Cost of Goods Sold - 32563

Schedule D (Form 990) 2021

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
	East Asia and the Pacific	0	1	Grantmaking	Research	31,483
	Europe (Including Iceland and Greenland)	0	1	Fundraising	Fundraising Support	21,940
	Europe (Including Iceland and Greenland)	0	4	Grantmaking	Research	238,914
	Europe (Including Iceland and Greenland)	0	1	Program Services	Learning Mgmt System	15,007
	Europe (Including Iceland and Greenland)	0	1	Program Services	Mission Tool Development	30,375
	Europe (Including Iceland and Greenland)	0	1	Program Services	Professional Membership	3,250
	North America (Canada & Mexico only)	0	3	Grantmaking	Research	295,386
	North America (Canada & Mexico only)	0	1	Program Services	Mission Support	68,946
	North America (Canada & Mexico only)	0	1	Program Services	Mission Tool Development	33,308
	North America (Canada & Mexico only)	0	1	Program Services	Professional Membership	18,000
	North America (Canada & Mexico only)	0	1	Program Services	Software Licenses	24,261
	North America (Canada & Mexico only)	0	1	Program Services	Research	1,000
	North America (Canada & Mexico only)	0	1	Public Relations	Public Relations	8,141
	Europe (Including Iceland and Greenland)	0	1	Program Services	Sponsorship of Mission Programs	102,500



3a	Sub-total ....	0	19			892,511
b	Total from continuation sheets to Part I ...	0	0			0
c	Totals (add lines 3a and 3b)	0	19			892,511

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2022

Schedule F (Form 990) 2022

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant
East Asia and the Pacific	Research	31,483
East Asia and the Pacific	Research	74,544
North America (Canada & Mexico only)	Research	74,544
North America (Canada & Mexico only)	Research	89,827
North America (Canada & Mexico only)	Research	145,385
Europe (Including Iceland and Greenland)	Research	75,000
Europe (Including Iceland and Greenland)	Research	75,000

2	Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......	5
3	Enter total number of other organizations or entities .......................	0

Schedule F (Form 990) 2022

Schedule F (Form 990) 2022Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2022

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2022

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ReturnReference	Explanation
Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds	AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, Part IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.
Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual
Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual

Schedule F (Form 990) 2022

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE G (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

Fundraising Activities.Complete if the organization answered "Yes" on Form 990, Part IV, line 17.

Form 990-EZ filers are not required to complete this part.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

YesNo

If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	Event 360 55 E Jackson Blvd Suite 1010 Chicago, IL60604	Fundraising Consultant		No	14,471,684	783,234	13,688,450
	Revunami Inc 228 E 85th St Suite 9C New York, NY10028	Marketing Consultant		No		14,061	-14,061
	RKD Group LLC 3400 Waterview Parkway Suite 250 Richardson, TX75080	Fundraising Consultant		No	24,004,781	533,010	23,471,771
	InKind Inc DBA GoodUnited 796 Meeting STreet Charleston, SC29403	Fundraising Consulting		No	1,484,191	33,423	1,450,768






Total . . . . . . . . . . . . . . . . . . . .					39,960,656	1,363,728	38,596,928

List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

CA, CO, CT, DC, FL, GA, AL, HI, ID, IL, IN, IA, KS, KY, LA, ME, AK, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, AZ, RI, SC, SD, TN, TX, UT, VT, VA, AR, WA, WV, WI, WY

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990) 2022

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 3 Day Series (event type)	(b) Event #2 Race-Walk Events (event type)	(c) Other events 50 (total number)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . . . .	14,385,465	20,377,979	2,725,124	37,488,568
2	Less: Contributions . . . .	14,171,508	19,569,955	1,926,871	35,668,334
3	Gross income (line 1 minus line 2) . . . . . .	213,957	808,024	798,253	1,820,234

4	Cash prizes . . . . .	0	0	0	0
5	Noncash prizes . . . .	15,601	731,448	21,957	769,006
6	Rent/facility costs . . . .	2,020,744	263,961	190,649	2,475,354
7	Food and beverages . . .	475,001	264,485	325,855	1,065,341
8	Entertainment . . . .	0	18,952	26,300	45,252
9	Other direct expenses . . .	1,351,776	2,643,606	183,539	4,178,921
10	Direct expense summary. Add lines 4 through 9 in column (d) . . . . . . . . . .				8,533,874
11	Net income summary. Subtract line 10 from line 3, column (d). . . . . . . . . .				-6,713,640

Part III

Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/Instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col.(a) through col.(c))
1	Gross revenue . . . . .

2	Cash prizes . . . . .
3	Noncash prizes . . . .
4	Rent/facility costs . . . .
5	Other direct expenses . . .

Volunteer labor . . . .

	Yes %
	No

	Yes %
	No

	Yes %
	No

Direct expense summary. Add lines 2 through 5 in column (d) . . . . . . . . . . right arrow

Net gaming income summary. Subtract line 7 from line 1, column (d). . . . . . . . . right arrow

Enter the state(s) in which the organization conducts gaming activities:

Is the organization licensed to conduct gaming activities in each of these states? . . . . . . . .

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? . . .

YesNo

If "Yes," explain:

Schedule G (Form 990) 2022

Page 3

Does the organization conduct gaming activities with nonmembers? . . . . . . . . . . .

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? . . . . . . . . . . . . . . . . .

YesNo

Indicate the percentage of gaming activity conducted in:

The organization's facility . . . . . . . . . . . . . . . . . .

13a

An outside facility . . . . . . . . . . . . . . . . . . . .

13b

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? . . . . . . . . . . . . . . . . . . . . . . . .

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? . . . . . . . . . . . . . . . . . . .

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

Return Reference	Explanation
Schedule G, Part II Net Income Summary	Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2023 were $35,668,334.

Schedule G (Form 990) 2022

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990.
lBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization
The Susan G Komen Breast Cancer Foundation Inc

Employer identification number
75-1835298

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient

that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) Alliance for Clinical Trials in Oncology	02-0464400	103,344	Research
(2) AMITA Health	36-2235165	12,600	Patient Care
(3) Barnes-Jewish Hospital	23-7309937	37,500	Patient Care
(4) Baylor College Medicine	74-1613878	347,799	Research
(5) Baylor University	74-1159753	330,000	Research
(6) Board of Regents of the University of	73-1563627	57,504	Research
(7) Boston University	04-2103547	199,448	Research
(8) Brigham and Women's Hospital	04-2312909	36,000	Research
(9) Burnham Institute for Medical Research	51-0197108	49,994	Research
(10) Cedars Sinai Medical Center	95-1644600	115,337	Research
(11) Columbia University Medical Center	13-5598093	386,422	Research
(12) Dana Farber Cancer Institute	04-2263040	892,588	Research
(13) Dana-Farber Cancer Institute Inc	04-2263040	392,380	Research
(14) Duke University Medical Center	56-0532129	546,914	Research
(15) Eastern Michigan University	38-2953297	87,500	Education
(16) ECOG Research and Education Foundation	39-1723095	101,486	Research
(17) Emory University	58-0566256	189,917	Research
(18) Georgetown University	52-2339873	5,815	Research
(19) Harvard Medical School	04-2103580	100,000	Research
(20) Indiana University (Indianapolis)	35-6001673	809,308	Research
(21) Johns Hopkins University	52-0595110	312,500	Research
(22) Johns Hopkins University	52-0595110	75,000	Research
(23) Lake County Health Department	59-3502843	5,105	Patient Care
(24) Leland Stanford Jr University	94-1156365	300,000	Research
(25) Loyola University Chicago	36-1408475	165,000	Research
(26) Mayo Clinic Jacksonville	59-3337028	220,000	Research
(27) McDonough County Health Department	37-6001537	4,419	Patient Care
(28) Memorial Sloan-Kettering Cancer Ctr	13-1924236	374,999	Research
(29) Mount Sinai School of Medicine	13-6171197	134,750	Research
(30) Oregon Health & Science University	75-2668014	429,396	Research
(31) Parkland Foundation	75-2089180	100,000	Patient Care
(32) Presence Hospitals PRV	34-4195126	6,300	Patient Care
(33) Princeton University	21-0634501	300,000	Research
(34) Roswell Park Alliance Foundation	16-1391608	75,000	Research
(35) Rush University Medical Center	36-2174823	220,000	Research
(36) Stanford University	94-1156365	375,137	Research
(37) SUNY at Stony Brook	14-1368361	33,783	Research
(38) The Ohio State University College	31-6025986	67,500	Research
(39) The Salk Institute	95-2160097	75,000	Research
(40) The University of Chicago	36-2177139	67,500	Research
(41) The University of Toledo	34-6401483	57,190	Research
(42) Touchette Regional Hospital Inc	37-1305510	37,500	Patient Care
(43) Univ of North Carolina at Chapel Hill	56-6001393	652,667	Research
(44) Univ of Texas MD Anderson Cancer Center	74-6001118	731,645	Research, Patient Care
(45) University of California at San Francis	94-6036493	283,458	Research
(46) University of California-Davis	94-6036494	100,000	Research
(47) University of Chicago	36-2177139	200,000	Research
(48) University of Kansas Center for Research	48-0680117	59,518	Research
(49) University of Kentucky Research Fndn	61-6033693	224,933	Research
(50) University of Michigan	38-6006309	180,000	Research
(51) University of North Carolina	56-6001393	220,000	Research
(52) University of Pennsylvania	23-1352685	571,450	Research, Patient Care
(53) University of Pittsburgh	25-0966691	29,958	Research
(54) University of Pittsburgh	25-0965591	135,319	Research
(55) University of Texas at Health Science Ctr	74-1587488	53,764	Research
(56) University of Utah	87-6000525	292,180	Research
(57) UT HSC - San Antonio	74-1586031	393,124	Research
(58) UT Southwestern Medical Center	74-6000203	150,000	Research
(59) Vanderbilt University Medical Center	62-0476822	486,465	Research
(60) Virginia Commonwealth University	54-6001758	240,000	Research
(61) Wake Forest University Health Sciences	22-3849199	59,926	Research
(62) Washington University at St Louis	43-0653611	131,984	Research
(63) Wayne State University	36-6028429	33,240	Research
(64) Weill Medical College of Cornell Univ	13-1623978	100,000	Research
(65) Yale University	03-0179440	307,788	Research

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2022

Page 2

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

(1) Patient Care Assistance @ $500	11994	3,081,750
(2) Patient Care Assistance @ $750	4109	5,997,000
(2)
(3)
(4)
(5)
(6)
(7)

Part IV

Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference

Explanation

Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.

SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.

Schedule I (Form 990) 2022

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990.
SchJMediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2022

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1Dana Brown Chief Operating Officer (Term 3/31/22)	(i) (ii)	136,744 ------------- 0	46,800 ------------- 0	1,213 ------------- 0	4,200 ------------- 0	1,380 ------------- 0	190,337 ------------- 0	0 ------------- 0
2Eunice Nakamura General Counsel and Corporate Secretary	(i) (ii)	244,099 ------------- 0	28,200 ------------- 0	1,579 ------------- 0	16,754 ------------- 0	6,933 ------------- 0	297,565 ------------- 0	0 ------------- 0
3Paula Schneider President and CEO	(i) (ii)	631,275 ------------- 0	252,285 ------------- 0	4,604 ------------- 0	20,057 ------------- 0	7,558 ------------- 0	915,779 ------------- 0	0 ------------- 0
4Ria Williams Chief Fin & Ops Officer	(i) (ii)	282,221 ------------- 0	34,800 ------------- 0	2,055 ------------- 0	16,874 ------------- 0	13,761 ------------- 0	349,711 ------------- 0	0 ------------- 0
5Lori Maris SVP, OPS SERVICES & SUPPORT	(i) (ii)	212,699 ------------- 0	25,800 ------------- 0	1,734 ------------- 0	8,401 ------------- 0	6,948 ------------- 0	255,582 ------------- 0	0 ------------- 0
6Catherine Olivieri SVP, Human Resources	(i) (ii)	243,713 ------------- 0	30,000 ------------- 0	3,362 ------------- 0	14,714 ------------- 0	11,705 ------------- 0	303,494 ------------- 0	0 ------------- 0
7Victoria Smart SVP, Mission	(i) (ii)	294,149 ------------- 0	34,800 ------------- 0	2,528 ------------- 0	13,911 ------------- 0	1,794 ------------- 0	347,182 ------------- 0	0 ------------- 0
8Srinivasu Avadhanula VP, BI Platform & Engineering	(i) (ii)	223,372 ------------- 0	24,960 ------------- 0	1,460 ------------- 0	12,379 ------------- 0	11,235 ------------- 0	273,406 ------------- 0	0 ------------- 0
9Kari Bodell VP, Development Programs Strategy	(i) (ii)	213,599 ------------- 0	24,600 ------------- 0	1,426 ------------- 0	12,375 ------------- 0	1,794 ------------- 0	253,794 ------------- 0	0 ------------- 0
10Sarah Rosales VP, Corporate Partnerships	(i) (ii)	227,827 ------------- 0	28,200 ------------- 0	1,331 ------------- 0	13,683 ------------- 0	15,668 ------------- 0	286,709 ------------- 0	0 ------------- 0
11Catherine Stone VP, Community Health	(i) (ii)	189,677 ------------- 0	22,000 ------------- 0	1,383 ------------- 0	11,337 ------------- 0	1,794 ------------- 0	226,191 ------------- 0	0 ------------- 0
12Michelle Strong VP, Marketing Strategy	(i) (ii)	207,548 ------------- 0	24,000 ------------- 0	1,632 ------------- 0	14,372 ------------- 0	7,988 ------------- 0	255,540 ------------- 0	0 ------------- 0

Schedule J (Form 990) 2022

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation

Schedule J (Form 990) 2022

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...	X	56	148,547	Cost
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( Gift bags/Gift Cards )	X	53	424,435	Cost
26 Other ( Event Supplies )	X	7	19,495	Cost
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2022)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
Schedule M, Part I Explanations of reporting method for number of contributions	Food inventory - Food & Beverage Number of contributions Other - Gift bags/Gift Cards Number of contributions

Schedule M (Form 990) (2022)

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

- TIN:

SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

The Susan G Komen Breast Cancer Foundation Inc

Employer identification number

75-1835298

Return Reference	Explanation
Form 990, Part I, Line 6 VOLUNTEERS	VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, THE SUSAN G. KOMEN 3 DAY SERIES, AND ADVOCACY PROGRAMS.
Form 990, Part III, Line 4 Program service accomplishments	SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING THE MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH: - RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL. -COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. - AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL-TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS INVESTED OVER $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2800 GRANTS AND MORE THAN 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE WORLD'S BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $3.2 BILLION IN COMMUNITY INVESTMENT FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, ADVOCACY, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. WITH THIS INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS, - DEVELOPMENT OF NEW TECHNOLOGIES AND TESTS, AND - NEW INTERVENTIONS THAT ARE CHANGING THE STANDARD OF BREAST CANCER CARE AND IMPROVING THE DELIVERY OF THAT CARE. OUR GOAL IS TO ADVANCE PERSONALIZED MEDICINE AND IMPROVE HEALTH OUTCOMES FOR EVERYONE. KOMEN HAS HAD MORE THAN 3,100 RESEARCH DISCOVERIES THAT ARE MOVING US CLOSER TO THAT GOAL. THIS INCLUDES OVER 700 NEW DISCOVERIES FOCUSED ON METASTATIC BREAST CANCER, MORE THAN 1,200 POTENTIAL TREATMENTS AND NEARLY 400 NEW STRATEGIES TO ELIMINATE BREAST CANCER DISPARITIES. THEY INCLUDE SUCH THINGS AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTH CARE DELIVERY TOOLS IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER AND THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 54 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF NINE ESTEEMED BREAST CANCER RESEARCHERS AND TWO NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE INDIVIDUALS JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY23, KOMEN AWARDED 49 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, PUERTO RICO AND PORTUGAL. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH FOCUSED THE DEVELOPMENT OF NEXT GENERATION-TARGETED THERAPIES AND THE DEVELOPMENT OF INTERVENTIONS TO ELIMINATE BREAST CANCER HEALTH DISPARITIES. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. A SUPPLEMENT TO PROMOTE INCLUSION FOR RESEARCH EXCELLENCE (ASPIRE) GRANTS ARE SUPPLEMENT GRANTS TO AMPLIFY EXISTING FUNDING TO ENHANCE THE DIVERSITY OF THE BREAST CANCER RESEARCH WORKFORCE BY PROVIDING ESTABLISHED BREAST CANCER SCIENTISTS WITH SUPPLEMENTAL FUNDING TO SUPPORT RESEARCH TRAINEES FROM COMMUNITIES HISTORICALLY MINORITIZED AND MARGINALIZED IN RESEARCH. THE 49 RESEARCH GRANTS AWARDED IN FY23 ARE: CAREER CATALYST RESEARCH GRANTS: JULIA MCGUINNESS, M.D., FROM COLUMBIA UNIVERSITY, WILL DEVELOP A NEW MODEL TO ACCURATELY PREDICT BREAST CANCER RISK FROM SCREENING MAMMOGRAMS. SHE WILL UTILIZE SAMPLES FROM A RACIALLY/ETHNICALLY DIVERSE POPULATION IN NEW YORK CITY TO ENSURE THE MODEL REPRESENTS ALL BREAST CANCER PATIENTS. SHEARWOOD MCCLELLAND, M.D., FROM CASE WESTERN UNIVERSITY IS TESTING HOW PATIENT NAVIGATION IMPACTS ACCESS TO SHORT-COURSE RADIATION THERAPY (RT) FOR BLACK BREAST CANCER PATIENTS AND HOW FINANCIAL TOXICITIES INFLUENCE RT ADHERENCE. THE GOAL OF THIS RESEARCH IS TO DEMONSTRATE HOW PATIENT NAVIGATION AND SHORT-COURSE RT CAN ALLEVIATE FINANCIAL BURDEN AND HELP BLACK BREAST CANCER PATIENTS COMPLETE THEIR RT TREATMENTS. THIS WORK WILL ALSO CREATE A NEW EDUCATIONAL TOOL FOR PATIENT NAVIGATORS THAT EDUCATES ON THE USE OF SHORT-COURSE RT TO OVERCOME EXISTING BARRIERS TO CARE AND IMPROVE TREATMENT OUTCOMES. ANAND NARAYAN, M.D., PH.D., FROM THE UNIVERSITY OF WISCONSIN-MADISON, WILL CREATE A FREE ELECTRONIC HEALTH RECORDS PROGRAM THAT WILL IMPROVE HOW CLINICIANS MONITOR DELAYS IN MAMMOGRAMS, AND WILL ALSO QUANTIFY BARRIERS TO SCREENING AND CREATE PATIENT-CENTERED INTERVENTIONS THAT IMPROVE ACCESS TO BREAST IMAGING. THE GOAL IS TO IMPROVE TIMELY ACCESS TO MAMMOGRAMS TO CATCH MORE CANCERS EARLIER, PARTICULARLY IN MINORITY, RURAL AND UNINSURED POPULATIONS. BRUNO BARUFALDI, PH.D., FROM THE UNIVERSITY OF PENNSYLVANIA, WILL DEVELOP AN ARTIFICIAL INTELLIGENCE SYSTEM THAT INCORPORATES RACIALLY UNBIASED DESCRIPTORS OF BREAST COMPLEXITY AND SOCIOECONOMIC STATUS TO BETTER IDENTIFY INDIVIDUALS THAT NEED SUPPLEMENTAL BREAST SCREENING. THE GOAL OF THIS STUDY IS TO ENSURE ALL PATIENTS RECEIVE ACCESS TO THE SCREENING TESTS THEY NEED TO IDENTIFY BREAST CANCER EARLY. PRIYANKA VERMA, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL AIM TO DEVELOP A NEW THERAPY FOR BRCA-MUTANT BREAST CANCERS THAT WILL TARGET AMPLIFIED IN LIVER CANCER 1 (ALC1), A PROTEIN THAT, WHEN INHIBITED, CAUSES DEATH OF BRCA-MUTANT BREAST CANCER CELLS WITH MINIMAL DAMAGE TO SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO PROVIDE AN INNOVATIVE AND PROMISING NEW THERAPY FOR HIGH-RISK WOMEN WITH BRCA MUTATIONS WHO CURRENTLY HAVE LIMITED TREATMENT OPTIONS. AIMILIA GASTOUNIOTI, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL USE DIGITAL MAMMOGRAMS AND BREAST TOMOSYNTHESIS FROM BLACK WOMEN TO ENHANCE ARTIFICIAL INTELLIGENCE (AI) MODELS THAT BETTER PREDICT BREAST CANCER RISK FOR THIS GROUP, WHO HAVE BEEN HISTORICALLY OVERLOOKED IN PAST RISK ASSESSMENTS. THE GOAL OF THIS WORK IS TO DEVELOP CLINICALLY RELEVANT AI METHODS THAT DIFFERENTIATE BETWEEN HIGH- AND LOW-RISK INDIVIDUALS, AND ADVANCE BREAST CANCER RISK ASSESSMENTS AND PRECISION SCREENING RECOMMENDATIONS FOR BLACK WOMEN.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	SARAH HILL, M.D., PH.D., FROM DANA- FARBER CANCER INSTITUTE, WILL INVESTIGATE THE ROLE OF A DNA DAMAGE REPAIR PROTEIN CALLED HBO1 IN TRIPLE NEGATIVE BREAST CANCER (TNBC). DR. HILL'S RESEARCH WILL DETERMINE IF HBO1 IS A PROMISING PHARMACEUTICAL TARGET FOR PATIENTS WITH TNBC, FOR WHOM TARGETED THERAPIES ARE URGENTLY NEEDED. LUCIA BORRIELLO, PH.D., FROM TEMPLE UNIVERSITY, WILL USE PRECLINICAL MODELS AND PATIENT DATA TO INVESTIGATE WHAT CAUSES BREAST TUMOR CELLS TO SPREAD AND LIE DORMANT BEFORE DEVELOPING INTO A DETECTABLE METASTATIC TUMOR. BY UNDERSTANDING THE CAUSES OF DORMANCY, DR. BORRIELLO HOPES THAT THERAPEUTIC STRATEGIES CAN BE DEVELOPED TO PREVENT DORMANT CELLS FROM DEVELOPING INTO METASTATIC BREAST CANCER. SHEHERYAR KABRAJI, BMBCH, OF ROSWELL PARK, WILL IDENTIFY MOLECULAR FEATURES ON TUMOR CELLS THAT CAUSE BLACK WOMEN WITH TRIPLE NEGATIVE BREAST CANCER (TNBC) TO RESPOND DIFFERENTLY TO NEOADJUVANT CHEMOTHERAPY THAN OTHER POPULATIONS, AND DETERMINE WHETHER THESE FEATURES COULD SERVE AS BIOMARKERS FOR THE DEVELOPMENT OF PERSONALIZED TNBC TREATMENTS. THIS RESEARCH COULD HELP REDUCE EXISTING DISPARITIES IN CHEMOTHERAPY BENEFITS AND ENSURE ALL TNBC PATIENTS HAVE EQUITABLE ACCESS TO THE BEST TREATMENTS POSSIBLE.NATHAN MERRILL, PH.D., FROM THE UNIVERSITY OF MICHIGAN, WILL EVALUATE A NOVEL DRUG COMBINATION THAT INCLUDES DNA DAMAGE RESPONSE (DDR) THERAPIES AND TREATMENTS THAT PREVENT TUMOR CELL GROWTH. USING PRECLINICAL MODELS AND CLINICAL MARKERS, THE GOAL OF THIS STUDY IS TO TARGET MARKERS OF SENSITIVITY AND RESISTANCE IN TRIPLE NEGATIVE BREAST CANCER (TNBC) TO HELP IDENTIFY DRUG COMBINATIONS THAT OFFER A PROMISING THERAPEUTIC STRATEGY FOR TNBC PATIENTS. GANG XIN, PH.D., FROM THE OHIO STATE UNIVERSITY, WILL INVESTIGATE HOW A POTENTIAL PROTEIN SWITCH COULD REGULATE TUMOR-ASSOCIATED MACROPHAGES (TAMS), A TYPE OF IMMUNE CELL, AND THE IMPACT ON THE RESPONSE OF BREAST TUMORS TO IMMUNOTHERAPY. THE GOAL OF THIS STUDY IS TO DEVELOP A TARGETED THERAPY THAT IMPROVES THE EFFICACY OF IMMUNOTHERAPY. ADRIENNE WAKS, M.D., FROM DANA FARBER CANCER INSTITUTE, WILL EXPLORE THE RELATIONSHIP BETWEEN ANTI-HER2 ANTIBODY THERAPY, ANTI-TUMOR IMMUNE RESPONSES AND CLINICAL OUTCOMES FOR PEOPLE WITH HER2+ BREAST CANCER. THE HOPE IS THAT THIS STUDY WILL IDENTIFY WHICH HER2+ PATIENTS WILL BENEFIT MOST FROM ANTI-HER2 THERAPIES AND GUIDE DEVELOPMENT OF NEW THERAPIES THAT WILL OVERCOME IMMUNE RESISTANCE FOR THESE PATIENTS. ERIKA CROSBY, PH.D., FROM DUKE UNIVERSITY, WILL USE A MOUSE MODEL TO INVESTIGATE HOW OBESITY IMPACTS RESPONSE TO IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER (TNBC), AND EVALUATE WHETHER THESE STUDY RESULTS CORRELATE WITH OBSERVATIONS FOR WOMEN PARTICIPATING IN THE CAROLINA BREAST CANCER STUDY. THIS RESEARCH WILL PROVIDE INSIGHT INTO THE PARADOX OF IMMUNOTHERAPY, OBESITY AND THEIR POTENTIAL EFFECTS IN TNBC. ISAAC CHAN, M.D., PH.D., FROM THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL CONDUCT A STUDY USING LYMPHOCYTES CALLED NATURAL KILLER CELLS THAT SUPPORT BREAST CANCER METASTASIS AND REPROGRAM THEM TO RETURN TO THEIR ORIGINAL TUMOR-FIGHTING ACTIVITY. THIS STUDY WILL HELP IDENTIFY PATIENTS WHO WOULD MOST BENEFIT FROM IMMUNOTHERAPIES, AS WELL AS INFLUENCE STRATEGIES FOR THE FUTURE DEVELOPMENT OF DRUGS THAT WILL MANIPULATE IMMUNE CELLS TO FIGHT METASTATIC TUMORS. ASPIRE GRANTS JULIE PALMER, SC.D., M.P.H., FROM BOSTON UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER ETIENNE X. HOLDER, PH.D., WHO WILL EXAMINE NEIGHBORHOOD-LEVEL PSYCHOSOCIAL FACTORS TO DETERMINE WHETHER CHRONIC PSYCHOSOCIAL DISTRESS LEADS TO THE ADVERSE BIOLOGICAL OUTCOMES THAT CONTRIBUTE TO THE DISPROPORTIONATELY HIGH BREAST CANCER MORTALITY EXPERIENCED BY BLACK WOMEN. THE GOAL OF THIS RESEARCH IS TO EXPLAIN THIS HIGH MORTALITY RATE AND DEVELOP INDIVIDUAL-LEVEL INTERVENTIONS SUCH AS MEDICATIONS AND MINDFULNESS TRAINING, AS WELL AS THE DEVELOPMENT OF NEW PROGRAMS AND POLICIES, TO COUNTERACT THE EFFECTS OF CHRONIC PSYCHOSOCIAL DISTRESS EXPERIENCED IN THESE COMMUNITIES. JENNIFER GUERRIERO, PH.D., FROM BRIGHAM AND WOMEN'S HOSPITAL, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CARLOS WAGNER DE SOUZA WANDERLEY, PH.D., WHO IS STUDYING HOW DIFFERENT FACTORS IN THE TUMOR MICROENVIRONMENT IMPACT THE RESPONSE OF BRCA-MUTANT TUMOR CELLS TO PARP INHIBITORS, A TYPE OF TARGETED THERAPY FOR TREATING TUMORS WITH A BRCA MUTATION. THE GOAL OF THIS RESEARCH IS TO PROVIDE INSIGHT INTO POTENTIAL COMBINATION THERAPIES THAT WOULD IMPROVE THE RESPONSE TO PARP INHIBITORS. HARIKRISHNA NAKSHATRI, PH.D., FROM INDIANA UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE ADEDEJI. K. ADEBAYO, D.V.M., WHO WILL STUDY THE IMPACT OF OXYGEN EXPOSURE ON TUMOR CELLS DERIVED FROM TUMORS ACQUIRED FROM THE KOMEN TISSUE BANK AT THE INDIANA UNIVERSITY SIMON COMPREHENSIVE CANCER CENTER. THE GOAL OF THIS RESEARCH IS TO IDENTIFY HOW DIFFERENT OXYGEN CONDITIONS MODIFY TUMOR SIGNALING, GROWTH AND RESPONSE TO BREAST CANCER TREATMENTS. MARIA SOSA, PH.D., FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CAROLINA RODRIGUEZ TIRADO, PH.D., WHO WILL INVESTIGATE HOW THE PROTEIN ZFP296 ALLOWS DISSEMINATED, DORMANT CANCER CELLS TO FORM A METASTATIC TUMOR. THE GOALS OF THIS PROJECT ARE TO ILLUSTRATE THE ROLE OF ZFP296 IN REACTIVATING DORMANT CANCER CELLS, IDENTIFY POSSIBLE THERAPIES AGAINST ZFP296, AND ULTIMATELY, TO USE THESE FINDINGS TO HELP PREVENT BREAST CANCER METASTASIS. JUSTIN BALKO, PH.D., PHARM.D., FROM VANDERBILT UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT BRANDIE TAYLOR, WHO WILL INVESTIGATE WHY HETEROGENEOUS LEVELS OF THE PROTEIN MHC-I WITHIN A SINGLE TUMOR CAN NEGATIVELY IMPACT BREAST TUMOR RESPONSE TO IMMUNOTHERAPY. THESE STUDIES WILL LEAD TO AN INCREASED UNDERSTANDING OF WHY SOME TUMORS DON'T RESPOND TO IMMUNOTHERAPY. TASNEEM BAWA-KHALFE, PH.D., FROM THE UNIVERSITY OF HOUSTON, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO KACIE WAITERS, WHO WILL INVESTIGATE HOW THE MODIFICATION OF DNA VIA A PROCESS CALLED SUMOYLATION (SUMO) REDUCES TREATMENT EFFICACY AND DRIVES PROGRESSION OF BREAST TUMORS IN ADVANCED ENDOCRINE RESISTANT HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW SUMO IS INVOLVED IN THIS PROCESS AND TO EVALUATE AND PRODUCE NOVEL THERAPIES THAT WILL PREVENT TUMOR PROGRESSION. MICHELLE MARTINEZ-MONTEMAYOR, PH.D., FROM THE UNIVERSIDAD CENTRAL DEL CARIBE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER LUZ V. ARROYO-CRUZ, PH.D., WHOSE STUDY WILL INVESTIGATE WHETHER A NATURAL STEROIDAL COMPOUND CAN TARGET SPECIFIC PROTEINS IN TUMOR CELLS, IMPAIRING THEM AND CAUSING THEM TO DIE, WITHOUT DAMAGING SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW THIS NATURAL COMPOUND CAN LEAD TO TUMOR CELL DEATH. MATTHEW BRADY, M.D., FROM THE UNIVERSITY OF CHICAGO, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT BRIANA BANKS FOR THIS RESEARCH, WHICH WILL DETERMINE WHETHER HIGHER LEVELS OF A STEROID HORMONE CALLED GLUCOCORTICOID (GC) MAY INCREASE THE RISK OF BREAST CANCER DURING CRITICAL TIMES OF DEVELOPMENT LIKE PUBERTY. USING PRECLINICAL MODELS OF BREAST CANCER, THEY WILL IDENTIFY HOW GC RELEASE AFFECTS THE DEVELOPMENT OF MAMMARY GLAND DUCTS AND DETERMINE WHETHER USE OF A GC-BLOCKING DRUG CAN REVERSE MANY OF THESE CHANGES THAT INCREASE BREAST CANCER RISK. CHRISTY HAGAN, PH.D., OF THE UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT HARMONY SAUNDERS, WHO WILL INVESTIGATE HOW PROGESTERONE TREATMENTS IMPACT BREAST CANCER. THIS STUDY WILL DETERMINE WHETHER ACTIVATION OF PROGESTERONE RECEPTORS IN THE MAMMARY GLAND ALLOWS TUMORS TO ESCAPE DETECTION BY THE IMMUNE SYSTEM AND AVOID CELL DEATH.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	JULIE RHOADES, PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT LOGAN NORTHCUTT, WHO WILL INVESTIGATE HOW ESTROGEN RECEPTOR (ER) SIGNALING IS REGULATED WHEN TUMOR CELLS METASTASIZE TO THE BONE USING A NOVEL MODEL OF BONE STIFFNESS. THE INFORMATION GAINED FROM THIS STUDY WILL HELP RESEARCHERS UNDERSTAND HOW BREAST CANCER CELLS RESPOND TO ENDOCRINE THERAPY IN THE BONE, THE MOST COMMON SITE OF METASTASIS IN ER+ BREAST CANCER. ZACHARY T. SCHUG, PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT KELSEY SALCIDO, WHO WILL INVESTIGATE THE RELATIONSHIP BETWEEN ALCOHOL CONSUMPTION AND BREAST CANCER RISK. BY DETERMINING WHETHER THE ACETATE FOUND IN ALCOHOLIC BEVERAGES SERVES AS A FUEL FOR TUMOR METABOLISM AND GROWTH. THE GOAL OF THIS STUDY IS TO IDENTIFY WAYS TO MITIGATE THE IMPACT OF ALCOHOL CONSUMPTION ON BREAST CANCER RISK. LEADERSHIP GRANTS: SCIENTIFIC ADVISORY BOARD MEMBER ALAN ASHWORTH, PH.D., OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, WILL IDENTIFY GENES THAT ALTER RESPONSE TO NEW FORMS OF IMMUNOTHERAPY CALLED CAR-T AND NK CELL THERAPY. THE GOAL OF THIS RESEARCH IS TO BRING NEW OPTIONS FOR IMMUNOTHERAPY TO PATIENTS WITH METASTATIC BREAST CANCER. KOMEN SCHOLAR DONALD MCDONNELL, PH.D., OF DUKE UNIVERSITY, RECEIVED FUNDS TO STUDY A PROTEIN CALLED LYPD3, WHICH IS ASSOCIATED WITH AGGRESSIVE BREAST CANCER. THROUGH THIS RESEARCH, DR. MCDONNELL HOPES TO DISCOVER NEW DRUGS FOR METASTATIC BREAST CANCER. KOMEN SCHOLAR, BEN H. PARK, M.D., PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL INVESTIGATE WHY MUTATIONS IN THE SF3B1 PROTEIN CAUSE BREAST CANCER. BY UNDERSTANDING HOW THESE MUTATIONS CAUSE BREAST CANCER, DR. PARK HOPES TO IDENTIFY NEW STRATEGIES TO THERAPEUTICALLY TARGET BREAST TUMORS WITH SF3B1 MUTATIONS. SCIENTIFIC ADVISORY BOARD MEMBER LISA A. CAREY, M.D., SC.M., OF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, WILL INVESTIGATE HOW TUMORS DEVELOP RESISTANCE TO ANTIBODY- DRUG CONJUGATE (ADC) TREATMENTS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY BIOMARKERS THAT INFORM ONCOLOGISTS HOW WELL A BREAST CANCER PATIENT'S TUMOR RESPONDS TO TREATMENT WITH ADCS KOMEN SCHOLAR DAWN HERSHMAN, M.D., OF COLUMBIA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL TO DETERMINE IF INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPROVES THE QUALITY OF LIFE FOR PATIENTS WITH METASTATIC BREAST CANCER THAT STRUGGLE WITH FOOD INSECURITY. THE GOAL OF THIS STUDY IS TO INVESTIGATE THE FEASIBILITY OF THESE INTERVENTIONS, WHILE PAVING THE WAY FOR A LARGER CLINICAL TRIAL THAT WILL INVESTIGATE HOW INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPACT BREAST CANCER OUTCOMES. SCIENTIFIC ADVISORY BOARD MEMBER LISA NEWMAN, M.D., OF WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, WILL STUDY THE GENETIC MAKEUP OF BREAST TUMORS FROM WOMEN OF AFRICAN ANCESTRY. THE GOAL OF THIS RESEARCH IS TO BETTER UNDERSTAND THE UNIQUE FEATURES OF THESE BREAST TUMORS TO ELIMINATE RACIAL DISPARITIES IN BREAST CANCER OUTCOMES. CHIEF SCIENTIFIC ADVISOR ANN PARTRIDGE, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL INVESTIGATE UNIQUE BIOLOGICAL AND PSYCHOSOCIAL CHARACTERISTICS IN YOUNG WOMEN WITH BREAST CANCER. THE GOAL OF THIS RESEARCH IS TO IMPROVE TREATMENT OUTCOMES AND QUALITY OF LIFE FOR YOUNG WOMEN WITH BREAST CANCER WHO OFTEN EXPERIENCE GREATER DISTRESS THAN OLDER PATIENTS WITH BREAST CANCER. KOMEN SCHOLAR OLUFUNMILAYO OLOPADE, M.D., OF THE UNIVERSITY OF CHICAGO, WAS AWARDED A GRANT TO INVESTIGATE DIFFERENCES IN TREATMENT RESPONSE BETWEEN WHITE AND BLACK BREAST CANCER PATIENTS. BY PROVIDING A BETTER UNDERSTANDING OF HOW BLACK WOMEN'S TUMORS RESPOND TO TREATMENTS, THIS STUDY WILL HELP IMPROVE OUTCOMES IN THIS POPULATION. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: KOMEN SCHOLAR JEFFREY M. ROSEN, PH.D., OF BAYLOR COLLEGE OF MEDICINE, WILL STUDY HOW MACROPHAGES, A TYPE OF IMMUNE CELL, AFFECT TRIPLE NEGATIVE BREAST CANCER (TNBC). THE GOAL OF THIS STUDY IS TO IDENTIFY NEW MACROPHAGE-TARGETED IMMUNOTHERAPY DRUGS THAT COULD BE USED IN FUTURE CLINICAL TRIALS TO TREAT METASTATIC TNBC. KOMEN SCHOLAR BRYAN SCHNEIDER, M.D., OF INDIANA UNIVERSITY, WAS AWARDED A GRANT TO STUDY A TOXIC SIDE EFFECT FROM CHEMOTHERAPY THAT OCCURS MORE FREQUENTLY IN AFRICAN AMERICAN BREAST CANCER PATIENTS COMPARED TO OTHER POPULATIONS. THE GOAL OF THIS STUDY IS TO DECREASE THE DISPARITY IN SURVIVAL RATES FOR AFRICAN AMERICAN BREAST CANCER PATIENTS THROUGH PERSONALIZED MEDICINE. KOMEN SCHOLAR CARLOS ARTEAGA, M.D., OF THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL INVESTIGATE WHY SOME ER+ BREAST TUMORS BECOME RESISTANT TO CDK4/6 INHIBITORS. THE GOAL OF THIS STUDY IS TO CIRCUMVENT RESISTANCE TO THESE DRUGS TO IMPROVE OUTCOMES FOR PATIENTS WITH METASTATIC ER+ BREAST CANCER. KOMEN SCHOLAR MYLES BROWN, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL STUDY HOW BREAST TUMORS FORM USING CUTTING-EDGE RNA SEQUENCING TECHNIQUES. THROUGH UNDERSTANDING THE FORMATION OF BREAST TUMORS, DR. BROWN HOPES TO UNCOVER NEW THERAPEUTIC TARGETS FOR BREAST CANCER PREVENTION KOMEN SCHOLAR SUSAN DOMCHEK, M.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL INVESTIGATE NEW STRATEGIES FOR HELPING WOMEN WITH BRCA1 AND BRCA2 MUTATIONS MAKE DECISIONS REGARDING BREAST CANCER SCREENING AND RISK-REDUCING SURGERY. THE GOAL OF THIS PROJECT IS TO CAPITALIZE ON NEW ADVANCES IN GENETIC TESTING TECHNOLOGY TO EMPOWER PATIENTS TO MAKE THE BEST DECISIONS FOR THEIR BREAST HEALTH. KOMEN SCHOLAR DAVID MANKOFF, M.D., PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WAS AWARDED FUNDS TO STUDY NEW APPLICATIONS OF PET MOLECULAR IMAGING IN BREAST CANCER. FROM THESE STUDIES, DR. MANKOFF EXPECTS TO IMPROVE DIAGNOSTIC CAPABILITIES FOR ALL BREAST CANCERS, BUT PARTICULARLY FOR THOSE DIFFICULT TO DETECT WITH CURRENT TECHNOLOGY, SUCH AS INVASIVE LOBULAR BREAST CANCER. KOMEN SCHOLAR HARIKRISHNA NAKSHATRI, PH.D., OF INDIANA UNIVERSITY, WILL STUDY A PROTEIN CALLED TONSL THAT IS ABNORMALLY INCREASED IN BREAST TUMORS AND LEADS TO RESISTANCE OF PARP INHIBITORS, THE TREATMENT OF CHOICE FOR PATIENTS WITH BRCA1/2 GENE MUTATIONS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY DRUGS THAT TARGET TONSL THAT CAN BE USED IN PATIENTS WITH BRCA1/2 MUTATIONS WHOSE TUMORS DEVELOP RESISTANCE TO PARP INHIBITORS. KOMEN SCHOLAR KATHY MILLER, M.D., OF INDIANA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL THAT WILL TEST WHETHER BLACK WOMEN BENEFIT FROM A NEW DRUG COMBINATION DESIGNED TO DECREASE HEIGHTENED INFLAMMATION THAT IS OFTEN OBSERVED IN BREAST CANCER IN BLACK WOMEN. AS BLACK WOMEN ARE 40% MORE LIKELY TO DIE FROM BREAST CANCER THAN WHITE WOMEN, THIS TRIAL HAS THE POTENTIAL TO CLOSE THE GAP OF THIS DISPARITY AND IMPROVE THE POOR OUTCOMES THAT BLACK WOMEN FACE. KOMEN SCHOLAR, ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL EVALUATING THE OPTIMAL STRATEGY FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH IMMUNOTHERAPY. THE GOAL OF THIS RESEARCH IS TO ENSURE THAT PATIENTS WITH NEWLY DIAGNOSED TNBC RECEIVE IMMUNOTHERAPY AT THE RIGHT TIME, IN AN OPTIMIZED FASHION. MBC COLLABORATIVE RESEARCH INITIATIVE KATHERINE REEDER-HAYES, M.D., OF UNIVERSITY OF NORTH CAROLINA CHAPEL-HILL AND DEVON CHECK, PH.D., OF DUKE UNIVERSITY ARE COLLABORATING ON A RESEARCH STUDY AS PART OF THE MBC-COLLABORATIVE RESEARCH INITIATIVE. THEY WILL WORK TOGETHER TO INCREASE OUR UNDERSTANDING OF THE KEY SOCIAL DETERMINANTS OF HEALTH (SDOH) OF METASTATIC BREAST CANCER (MBC) DEVELOPMENT AND OUTCOMES THROUGH RECRUITING A DIVERSE GROUP OF WOMEN LIVING WITH MBC TO INVESTIGATE HOW CHRONIC STRESS, INFLAMMATION AND IMMUNE SYSTEM CHANGES IMPACT BLACK AND WHITE WOMEN WITH MBC TO IMPROVE PATIENT OUTCOMES. OPPORTUNITY GRANTS: ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL RECEIVE FUNDING TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC, A GROUP OF 19 CLINICAL SITES, PROVIDES A FORUM WHERE INVESTIGATORS, ADVOCATES, COORDINATORS, SCIENTISTS AND BIOSTATISTICIANS WORK TOGETHER TO PLAN AND REFINE CLINICAL TRIALS, ADVANCING BREAST CANCER KNOWLEDGE MORE EFFICIENTLY ACROSS THE FIELD. MORE THAN HALF OF TBCRC TRIALS HAVE FOCUSED ON METASTATIC BREAST CANCER. MELISSA TROESTER, PH.D., OF THE UNIVERSITY OF NORTH CAROLINA, WILL RECEIVE FUNDING TO CONTINUE THE CAROLINA BREAST CANCER STUDY, INTEGRATING CLINICAL, BIOLOGICAL, AND SOCIAL INFORMATION TO DETERMINE HOW DISPARITIES ARISE ACROSS MULTIPLE LEVELS, FROM THE BIOLOGY OF THEIR TUMORS TO THE FACTORS, THAT IMPACT THEIR CARE WITHIN THEIR COMMUNITIES. THESE STUDIES WILL IDENTIFY INTERVENTIONS THAT IMPROVE OUTCOMES AND CLOSE THE RACIAL GAP IN BREAST CANCER SURVIVAL FOR BLACK WOMEN.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	MICHELE COTE, PH.D., OF INDIANA UNIVERSITY (IU), WILL RECEIVE FUNDING TO SUPPORT A PARTNERSHIP BETWEEN THE SUSAN G. KOMEN TISSUE BANK (KTB) AND KOMEN'S BIG DATA FOR BREAST CANCER (BD4BC) INITIATIVE, A PROGRAM DESIGNED TO EXPLORE THE POWER OF BIG DATA FOR ADVANCING RESEARCH AND IMPROVING BREAST CANCER PATIENT CARE AND OUTCOMES. THIS GRANT WILL SUPPORT THE COLLECTION AND STORAGE OF SALIVA FOR PATIENT-DRIVEN RESEARCH. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED MORE THAN 3 MILLION PAGE VIEWS DURING FY23. KOMEN USED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG TO EDUCATE PEOPLE ABOUT THE ROLE CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, AND EMPOWERING PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, WITH PERSONALIZED SUPPORT AVAILABLE THROUGH THE KOMEN BREAST CARE HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN, FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACT SHEETS, AND C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS. IN ADDITION, IN FY23 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 12 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. WE OFFER ON-DEMAND VIDEOS OF THESE EVENTS IN BOTH ENGLISH AND SPANISH FOR THOSE NOT ABLE TO ATTEND LIVE. THE MBC IMPACT SERIES ALSO OFFERS REGULAR NEWSLETTERS AND QUARTERLY WELLNESS WEDNESDAY VIDEOS FOCUSED ON QUALITY OF LIFE AND OVERALL WELLNESS TOPICS. PATIENT SUPPORT WIDESPREAD BARRIERS TO CARE CONTRIBUTE TO POOR OUTCOMES AND DEATH FROM BREAST CANCER. THESE BARRIERS INCLUDE SOCIOECONOMIC FACTORS, A LACK OF ACCESS TO CARE AND INFORMATION, AND DISCRIMINATION IN HEALTH CARE AND QUALITY OF CARE. SUSAN G. KOMEN'S PATIENT CARE CENTER (PCC) PROVIDES INDIVIDUALIZED CARE TO HELP ENSURE THE BEST POSSIBLE OUTCOMES FOR EVERY PERSON IN NEED OF SUPPORT THROUGHOUT THEIR BREAST CANCER JOURNEY. OUR TEAM OF CULTURALLY RESPONSIVE NAVIGATORS PROVIDED MORE THAN 42,000 SERVICES TO OVER 30,000 PEOPLE THIS YEAR, INCLUDING: * ANSWERS TO QUESTIONS ABOUT BREAST CANCER RISK. * EMOTIONAL SUPPORT AND GUIDANCE IN ADDRESSING FEELINGS AND OTHER CONCERNS. * INFORMATION ABOUT BREAST CANCER SCREENING, TREATMENT OPTIONS, CLINICAL TRIALS, SUPPORT RESOURCES, AND GENETIC COUNSELING AND TESTING. * ACCESS TO NO-COST SCREENING MAMMOGRAMS AND DIAGNOSTIC SERVICES BASED ON INCOME ELIGIBILITY. * FINANCIAL ASSISTANCE FOR INCOME-ELIGIBLE BREAST CANCER PATIENTS IN TREATMENT OR LIVING WITH METASTATIC BREAST CANCER. * NAVIGATING THE HEALTH CARE SYSTEM, INCLUDING COMMUNICATING WITH HEALTH CARE PROVIDERS, UNDERSTANDING TREATMENT OPTIONS AND ACCESSING SUPPORT SERVICES. THE KOMEN PCC TEAM IS MADE UP OF MORE THAN 50 HIGHLY SKILLED PROFESSIONALS WHO ARE AS DIVERSE AS THOSE WE SERVE . OUR CARING AND COMPASSIONATE TEAM INCLUDES ONCOLOGY SOCIAL WORKERS, BILINGUAL SPECIALISTS, SUBJECT MATTER EXPERTS AND BREAST CANCER SURVIVORS FROM AROUND THE COUNTRY WHO UNDERSTAND THAT EVERYONE'S HEALTH CARE JOURNEY IS UNIQUE, THUS PROVIDING INDIVIDUALIZED CARE TO ENSURE THE BEST POSSIBLE OUTCOMES FOR EACH PERSON. METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE (MBCCRI) WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SELECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER. INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES IS BEING VALIDATED. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH AND CLINICAL CARE. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 4 MILLION BREAST CANCER SURVIVORS AND THOSE LIVING WITH THE DISEASE IN THE U.S. AS WELL AS THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THE CENTER FOR PUBLIC POLICY IS THE CORNERSTONE OF KOMEN'S MISSION, TO END BREAST CANCER FOREVER, THROUGH SOUND PUBLIC POLICY AND ADVOCACY COUPLED WITH SCIENTIFIC PROGRESS AND PATIENT SUPPORT SERVICES DESIGNED TO OVERCOME BARRIERS TO CARE. THE CENTER FOR PUBLIC POLICY IS THE DRIVING FORCE THAT ENSURES THE VOICE OF BREAST CANCER PATIENTS, SCIENTISTS, HEALTH CARE PROFESSIONALS, CAREGIVERS, AND ENGAGED MEMBERS OF THE PUBLIC WILL BE HEARD BY GOVERNMENT REGULATORS ON LOCAL, STATE AND NATIONAL LEVELS. KOMEN BELIEVES THAT ONLY THROUGH INFORMED GOVERNMENT ACTION CAN BROAD, SYSTEMIC AND LASTING CHANGES BE MADE TO PROTECT BREAST CANCER PATIENTS.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	KOMEN'S 2022-2023 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.
Form 990, Part VI, Line 1a Executive Committee	THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.
Form 990, Part VI, Line 11b Review of form 990 by governing body	MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.
Form 990, Part VI, Line 12c Conflict of interest policy	KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, DIRECTOR, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, EMPLOYEE, AND VOLUNTEER TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN REQUIRES ALL BOARD MEMBERS, OFFICERS, DIRECTORS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW AND EXECUTE THE CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.
Form 990, Part VI, Line 15a Process to establish compensation of top management official	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 15b Process to establish compensation of other employees	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 19 Required documents available to the public	KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST.
Form 990, Part IX, Line 1	FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST THREE YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH CENTERED ON THE PRIMARY FOCUS OF METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISAPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $40 MILLION IN NEW RESEARCH AWARDS OVER THE PAST TWO FISCAL YEARS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT.
Form 990, Part XI, Line 9 Other changes in net assets or fund balances	RESCINDED GRANTS - 1101560; Program COGS - -32562;

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) 2021

Additional Data

Software ID:	22016089
Software Version:	2022v5.0

1	Briefly describe the organization’s mission or most significant activities: OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAK-THROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	19
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	19
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a) ......	5	468
6	Total number of volunteers (estimate if necessary) .............	6	7,089
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	6,104
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	99,456,148	111,805,407
9	Program service revenue (Part VIII, line 2g) .........	2,500	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	7,437,450	2,453,577
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	4,365,358	-6,661,279
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	111,261,456	107,597,705
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	25,691,669	29,280,228
14	Benefits paid to or for members (Part IX, column (A), line 4).....		0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	36,149,496	45,865,289
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	1,181,706	1,363,728
b	Total fundraising expenses (Part IX, column (D), line 25) 27,230,240
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	37,609,513	40,554,624
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	100,632,384	117,063,869
19	Revenue less expenses. Subtract line 18 from line 12.......	10,629,072	-9,466,164
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	207,354,061	192,631,082
21	Total liabilities (Part X, line 26).............	59,717,916	62,957,218
22	Net assets or fund balances. Subtract line 21 from line 20.....	147,636,145	129,673,864

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 48,712,358 including grants of $ 10,610,338 ) (Revenue $ 0 )
	PATIENT CARE: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.

4b	(Code: ) (Expenses $ 24,634,101 including grants of $ 18,669,890 ) (Revenue $ 0 )
	GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.

4c	(Code: ) (Expenses $ 3,359,841 including grants of $ 0 ) (Revenue $ 0 )
	PUBLIC POLICY AND ADVOCACY: INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses76,706,300

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	3,707,675	0	247,615

1a	Federated campaigns..		1a	432,565
b	Membership dues..		1b	0
c	Fundraising events..		1c	35,668,334
d	Related organizations		1d	0
e	Government grants (contributions)		1e	0

f	All other contributions, gifts, grants, and similar amounts not included above		1f	75,704,508

g	Noncash contributions included in lines 1a - 1f:$		1g	592,477

h Total. Add lines 1a-1f.......		111,805,407

		Business Code
2a
b
c
d
e
f	All other program service revenue.		0	0	0	0
g	Total. Add lines 2a–2f .....		0

3 Investment income (including dividends, interest, and othersimilar amounts) ......			1,438,781			1,438,781
4 Income from investment of tax-exempt bond proceeds			0			0
5 Royalties...........			0			0
		(ii) Personal	(i) Real
6a	Gross rents	0	0	6a
b	Less: rental expenses	0	0	6b
c	Rental income or (loss)	0	0	6c
d	Net rental income or (loss).......			0	0	0	0
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory	0	3,316,237	7a
b	Less: cost or other basis and sales expenses	0	2,301,441	7b
c	Gain or (loss)	0	1,014,796	7c
d	Net gain or (loss).........			1,014,796	0	0	1,014,796
8a	Gross income from fundraising events (not including $ 35,668,334of contributions reported on line 1c). See Part IV, line 18 ....
			8a	1,820,234
b	Less: direct expenses ...		8b	8,533,874
c	Net income or (loss) from fundraising events..			-6,713,640		0	-6,713,640
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a	29,627
b	Less: direct expenses ...		9b	45,162
c	Net income or (loss) from gaming activities..			-15,535	0	0	-15,535
10a	Gross sales of inventory, less returns and allowances ..
			10a	107,070
b	Less: cost of goods sold ..		10b	65,932
c	Net income or (loss) from sales of inventory..			41,138	0	0	41,138
Business Code			Miscellaneous Revenue
11a	OTHER INCOME		900099	26,758	0	6,104	20,654
b				0	0	0	0
c				0	0	0	0
d	All other revenue ....			0	0	0	0
e	Total. Add lines 11a–11d ......			26,758
12	Total revenue. See instructions.....			107,597,705	0	6,104	-4,213,806

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	19,635,695	19,635,695
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........	9,078,750	9,078,750
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	565,783	565,783
4	Benefits paid to or for members .......	0	0
5	Compensation of current officers, directors, trustees, and key employees ...........	2,482,405	1,282,179	538,632	661,594
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........	0	0	0	0
7	Other salaries and wages........	36,277,286	18,726,067	7,828,981	9,722,238
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	1,479,554	779,973	303,129	396,452
9	Other employee benefits .......	3,014,565	1,502,541	748,043	763,981
10	Payroll taxes ...........	2,611,479	1,337,671	560,570	713,238
11	Fees for services (non-employees):
a	Management ......	0	0	0	0
b	Legal .........	150,411	60,819	29,864	59,728
c	Accounting ...........	342,030	0	342,030	0
d	Lobbying ...........	293,520	293,520	0	0
e	Professional fundraising services. See Part IV, line 17	1,363,728			1,363,728
f	Investment management fees ......	0	0	0	0
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	0	0	0	0
12	Advertising and promotion ....	5,738,163	3,331,081	198,565	2,208,517
13	Office expenses .......	16,194,959	8,190,560	162,466	7,841,933
14	Information technology ......	2,065,603	846,897	619,681	599,025
15	Royalties ..	0	0	0	0
16	Occupancy ...........	174,523	107,985	29,887	36,651
17	Travel ............	1,194,739	589,628	341,009	264,102
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .	0	0	0	0
19	Conferences, conventions, and meetings ....	224,153	97,027	95,686	31,440
20	Interest ...........	0	0	0	0
21	Payments to affiliates .......	0	0	0	0
22	Depreciation, depletion, and amortization ..	1,162,453	904,513	135,072	122,868
23	Insurance ...	499,600	499,600
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	CONSULT & PROF. FEES	6,582,084	5,401,593	389,052	791,439
b	EQUIP RENTAL & MAINT	3,127,554	2,008,073	401,706	717,775
c	MERCHANT SERVICES & BANK FEES	1,765,647	1,022,682	105,221	637,744
d	EVENT PRODUCTION	235,470	113,585	14,066	107,819
e	All other expenses	803,715	330,078	283,669	189,968
25	Total functional expenses. Add lines 1 through 24e	117,063,869	76,706,300	13,127,329	27,230,240
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).	48,508,025	24,374,495	1,206,569	22,926,961

1	Cash–non-interest-bearing ........			0	1	0
2	Savings and temporary cash investments .........			23,067,395	2	11,205,049
3	Pledges and grants receivable, net ......			15,045,253	3	15,405,966
4	Accounts receivable, net .............			0	4	0
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
				0	5	0
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
				0	6	0
7	Notes and loans receivable, net ...........			0	7	0
8	Inventories for sale or use ............			9,577	8	47,380
9	Prepaid expenses and deferred charges ......			2,120,424	9	1,613,365
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	13,932,941
b	Less: accumulated depreciation	10b	9,579,406	3,645,471	10c	4,353,535
11	Investments—publicly traded securities .			119,988,473	11	114,281,787
12	Investments—other securities. See Part IV, line 11 .....			43,470,000	12	43,470,000
13	Investments—program-related. See Part IV, line 11 ..			0	13
14	Intangible assets ...............			0	14
15	Other assets. See Part IV, line 11 ...........			7,468	15	2,254,000
16	Total assets. Add lines 1 through 15 (must equal line 33)...			207,354,061	16	192,631,082

17	Accounts payable and accrued expenses .....	9,791,057	17	9,306,708
18	Grants payable ...	49,697,151	18	53,366,811
19	Deferred revenue .........	229,708	19	283,699
20	Tax-exempt bond liabilities .........	0	20	0
21	Escrow or custodial account liability. Complete Part IV of Schedule D	0	21	0
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
		0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..	0	23	0
24	Unsecured notes and loans payable to unrelated third parties ..	0	24	0
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	0	25	0
26	Total liabilities. Add lines 17 through 25..	59,717,916	26	62,957,218

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	98,403,421	27	84,243,927
28	Net assets with donor restrictions ...........	49,232,724	28	45,429,937
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....	0	29	0
30	Paid-in or capital surplus, or land, building or equipment fund ...	0	30	0
31	Retained earnings, endowment, accumulated income, or other funds	0	31	0
32	Total net assets or fund balances ...........	147,636,145	32	129,673,864
33	Total liabilities and net assets/fund balances ........	207,354,061	33	192,631,082

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No